Antibiotics Market Overview:
The global antibiotics market generated $42,335 million in 2017, and is projected to reach $50,374 million by 2025, growing at a CAGR of 2.1% from 2018 to 2025.
Antibiotic is an antimicrobial substance, which are used in the treatment and prevention of bacterial infections, as well as used rarely to combat protozoan infections. Antibiotics are the medicines that either discontinue bacteria from growing or destroy bacteria straight referred as bacteriostatic and bactericidal antibiotics respectively. Easy accessibility of antibiotics at drug stores and in hospitals with prescription or without prescription fuels their consumption across the world. Moreover, increases antibiotics demand during transplants, dialysis, suppressed immune system, joint replacement, and others boosts the market growth.
Surge in demand for antibiotics, owing to increased consumption in low- & middle-income countries and rise in prevalence of infectious diseases are the key factors that boost the growth of the global antibiotics market. In addition, development of novel approaches for new antibiotics to treat bacterial infections and increase in clinical trials to determine safety & efficacy of the antibiotics drive the market growth. However, development of antibiotic resistance, driven by misuse of antibiotics, and time taken for regulatory approval are projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and introduction of novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer lucrative opportunities for the market players.
The global antibiotics market is segmented based on class, drug origin, spectrum of activity, route of administration, and region. On the basis of class, the market is classified as beta lactam & beta lactamase inhibitors, macrolides, quinolones, and others. The beta lactam & beta lactamase inhibitors segment is further segmented into penicillin, cephalosporin, monobactam, and carbapenem. Depending on drug origin, the antibiotics market is categorized into natural, semisynthetic, and synthetic. According to the spectrum of activity, it is bifurcated into broad-spectrum antibiotic and narrow-spectrum antibiotic. Based on route of administration, it is segregated into oral, intravenous, and others. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Antibiotics Market:
This report provides a detailed quantitative analysis of the current market trends and future estimations from 2018 to 2025, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the global antibiotics market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
Antibiotics Key Market Segments:
By Class
Beta Lactam & Beta Lactamase Inhibitors
Penicillin
Cephalosporin
Carbapenem
Monobactam
Quinolones
Macrolides
Others
By Drug Origin
Natural
Semisynthetic
Synthetic
By Spectrum of Activity
Broad-spectrum Antibiotic
Narrow-spectrum Antibiotic
By Route of Administration
Oral
Intravenous
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
Spain
Italy
UK
Rest of Europe
Asia-Pacific
Australia
Japan
India
China
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
KEY MARKET PLAYERS
Abbott Laboratories
Allergan Plc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc.
Merck & Co. Inc.
Mylan N.V.
Novartis International AG (Sandoz)
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
The other players in the value chain include (profiles not included in the report):
Aurobindo Pharma
Bayer HealthCare
Eli Lilly
Lupin Pharmaceuticals
Sun Pharmaceutical
Shionogi
The global antibiotics market generated $42,335 million in 2017, and is projected to reach $50,374 million by 2025, growing at a CAGR of 2.1% from 2018 to 2025.
Antibiotic is an antimicrobial substance, which are used in the treatment and prevention of bacterial infections, as well as used rarely to combat protozoan infections. Antibiotics are the medicines that either discontinue bacteria from growing or destroy bacteria straight referred as bacteriostatic and bactericidal antibiotics respectively. Easy accessibility of antibiotics at drug stores and in hospitals with prescription or without prescription fuels their consumption across the world. Moreover, increases antibiotics demand during transplants, dialysis, suppressed immune system, joint replacement, and others boosts the market growth.
Surge in demand for antibiotics, owing to increased consumption in low- & middle-income countries and rise in prevalence of infectious diseases are the key factors that boost the growth of the global antibiotics market. In addition, development of novel approaches for new antibiotics to treat bacterial infections and increase in clinical trials to determine safety & efficacy of the antibiotics drive the market growth. However, development of antibiotic resistance, driven by misuse of antibiotics, and time taken for regulatory approval are projected to impede the market growth. On the contrary, discovery of advanced prospect molecules and introduction of novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer lucrative opportunities for the market players.
The global antibiotics market is segmented based on class, drug origin, spectrum of activity, route of administration, and region. On the basis of class, the market is classified as beta lactam & beta lactamase inhibitors, macrolides, quinolones, and others. The beta lactam & beta lactamase inhibitors segment is further segmented into penicillin, cephalosporin, monobactam, and carbapenem. Depending on drug origin, the antibiotics market is categorized into natural, semisynthetic, and synthetic. According to the spectrum of activity, it is bifurcated into broad-spectrum antibiotic and narrow-spectrum antibiotic. Based on route of administration, it is segregated into oral, intravenous, and others. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Antibiotics Market:
This report provides a detailed quantitative analysis of the current market trends and future estimations from 2018 to 2025, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the global antibiotics market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
Antibiotics Key Market Segments:
By Class
Beta Lactam & Beta Lactamase Inhibitors
Penicillin
Cephalosporin
Carbapenem
Monobactam
Quinolones
Macrolides
Others
By Drug Origin
Natural
Semisynthetic
Synthetic
By Spectrum of Activity
Broad-spectrum Antibiotic
Narrow-spectrum Antibiotic
By Route of Administration
Oral
Intravenous
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
Spain
Italy
UK
Rest of Europe
Asia-Pacific
Australia
Japan
India
China
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
KEY MARKET PLAYERS
Abbott Laboratories
Allergan Plc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc.
Merck & Co. Inc.
Mylan N.V.
Novartis International AG (Sandoz)
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
The other players in the value chain include (profiles not included in the report):
Aurobindo Pharma
Bayer HealthCare
Eli Lilly
Lupin Pharmaceuticals
Sun Pharmaceutical
Shionogi
Table of Contents
CHAPTER 1: INTRODUCTION
Chapter 2: EXECUTIVE SUMMARY
Chapter 3: MARKET OVERVIEW
Chapter 4: ANTIBIoTICS MARKET, BY CLASS
Chapter 5: ANTIBIoTICS MARKET, BY DRUG ORIGIN
Chapter 6: ANTIBIoTICS MARKET, BY SPECTRUM OF ACTIVITY
Chapter 7: ANTIBIoTICS MARKET, BY ROUTE OF ADMINISTRATION
Chapter 8: ANTIBIoTICS MARKET, BY GEOGRAPHY
Chapter 9: COMPANY PROFILES
List Of Tables
List of Figures
Executive Summary
According to this report titled, 'Antibiotics Market by Class, Drug Origin, Spectrum of Activity, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2018-2025,' the global antibiotics market generated $42,335 million in 2017, and is projected to reach $50,374 million by 2025, growing at a CAGR of 2.1% from 2018 to 2025. The beta lactam & beta lactamase inhibitors segment accounted for more than three-fifth of the total market share in 2017.Antibiotic is a medication used to either inhibit or prevent bacterial infections referred as bactericidal and bacteriostatic antibiotics, respectively. Various types of antibiotics such as penicillin, cephalosporin, carbapenem, and monobactam are available in pharmacies and hospitals that are used to treat infectious diseases.
The antibiotics market is expected to exhibit significant growth during the forecast period, due to rise in demand for new generation antibiotics that can resolve the issue of antimicrobial resistance. In addition, development of novel approaches for new antibiotics for treating bacterial infections and increase in number of clinical trials supplement the growth of the antibiotics market. However, development of antibiotic resistance, driven by misuse of antibiotics, and time taken for the regulatory approval restrain the market growth. On the contrary, the discovery of advanced prospect molecules and introduction of novel combination therapies to treat antibiotic-resistant microbial infections are expected to provide new opportunities for market players in the near future.
Based on class, the global antibiotics market is categorized into beta lactam & beta lactamase inhibitors, quinolones, macrolides, and others. The quinolones segment is anticipated to exhibit the highest CAGR during forecast period, due to upsurge in demand for broad-spectrum, bactericidal activity; new generation quinolones; enhanced oral bioavailability; superior tissue penetration; and improved safety & tolerability.
By route of administration, the market is classified into oral, intravenous, and others. The intravenous segment was the major revenue contributor in 2017, and is projected to continue this trend during the forecast period, due to increase in incidence of severe infections. Moreover, as intravenous antibiotics are administered in higher concentrations, they reach in the tissues faster as compared to oral antibiotics.
Asia-Pacific is expected to remain dominant throughout the forecast period attributable to increased antibiotics consumption, their easy availability, and rise in sale of over-the-counter drugs. However, LAMEA is expected to experience the highest growth rate during the forecast period, majorly due to no obligations on antibiotics use in this region.
The report provides a comprehensive analysis of the key players operating in the global antibiotics market, namely, Abbott Laboratories, Allergan Plc., F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck & Co. Inc., Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.
The other players in the value chain include Aurobindo Pharma, Bayer HealthCare, Eli Lilly, Lupin Pharmaceuticals, Sun Pharmaceutical, Shionogi, and others.
Key Findings of the Antibiotics Market:
Based on spectrum of activity, the broad-spectrum antibiotic segment is expected to experience rapid growth in the market, and is projected to grow at a CAGR of 2.4% from 2018 to 2025.
Depending on route of administration, the oral segment is expected to exhibit the highest CAGR during the forecast period.
By drug origin, the semisynthetic segment was the major revenue contributor in 2017, and is anticipated to continue this trend during the forecast period.
U.S. generated the highest revenue in the global antibiotics market in 2017, accounting for more than one-fifth of the global market in 2017.
LAMEA is estimated to grow at a CAGR of 3.5% during the forecast period.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
